Bristol-Myers Squibb CoMIL:1BMY +3.55%50 Gross Margin % is 70.22% as of Mar. 2026, which is 2% below its 10-year median of 71.83. GuruFocus rates MIL:1BMY with a GF Score™ of 50/100 and a GF Value™ of €47.54 (Fairly Valued). The stock has 6 warning signs investors should review. Among 937 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 81.96% on this metric.
MIL:1BMY's Gross Margin % is ranked better than 81.96% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs MIL:1BMY: 70.45
Bristol-Myers Squibb Co had a gross margin of 70.22% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Bristol-Myers Squibb Co was -1.20% per year.
Bristol-Myers Squibb Co (MIL:1BMY) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bristol-Myers Squibb Co had a gross margin of 70.22% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bristol-Myers Squibb Co Gross Margin % Related Terms
Bristol-Myers Squibb Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1BMY vs PFE, GILD, AMGN: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bristol-Myers Squibb Co (MIL:1BMY) has a Gross Margin % of 70.22% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Bristol-Myers Squibb Co and its competitors. This is near median its historical median of 71.83. Over the past decade, Bristol-Myers Squibb Co's Gross Margin % has ranged from 69.10 to 78.57. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #169 out of 937 companies in the Drug Manufacturers industry, placing it in the top 18%.
Is Bristol-Myers Squibb Co's Gross Margin % too high?
Bristol-Myers Squibb Co's current Gross Margin % of 70.22% is near median its 10-year median of 71.83. Over the past 10 years, this metric has ranged from a low of 69.10 to a high of 78.57. The Drug Manufacturers industry median Gross Margin % is 48.46. Bristol-Myers Squibb Co's value of 70.22% is 44.9% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #169 out of 937 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Gross Margin % compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #169 out of 937 companies for Gross Margin %. This places Bristol-Myers Squibb Co in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.46. Bristol-Myers Squibb Co's value of 70.22% is 44.9% above this benchmark. Historically, Bristol-Myers Squibb Co's own Gross Margin % has ranged from 69.10 to 78.57 over the past decade. While the company's 10-year median is 71.83 vs. the industry median of 48.46, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Gross Margin % of 70.22% is 44.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Gross Margin % is 70.22%, which is near median its own 10-year median of 71.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (MIL:1BMY) is currently considered Fairly Valued. The stock's GF Value™ is €47.54, compared to a current price of €50.38 — trading 6% above its estimated fair value. The current Gross Margin % is 70.22%, which is near median its 10-year median of 71.83 and 44.9% above the Drug Manufacturers industry median of 48.46. Bristol-Myers Squibb Co's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bristol-Myers Squibb Co (MIL:1BMY), the current Gross Margin % is 70.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of €50.38 is trading 6% above its estimated GF Value™ of €47.54.
GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.
Key valuation signals for MIL:1BMY:
Gross Margin %: 70.22% (near median its 10-year median of 71.83)
GF Value™: €47.54 vs. price of €50.38 (6% above fair value)
Industry Position: 44.9% above the Drug Manufacturers median (#169 of 937)
No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
50GF Score
Get the complete analysis for MIL:1BMY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1BMY has been successfully added to your 
